Saturday, January 07, 2006

Statistically worth watching?

I know this is a bit dated, but I kept it in my "blogbites" file and offer it to you as an energizing start to your New Year":

From the Chicago Tribune, Wednesday, September 14 2005:

Headline: FDA panel rejects Abbot cancer pill

"Many drug industry observers were watching Abbott's submission because it used data that, statistically, failed to show the drug was effective in two clinical trials."

Yes, it does seem like this would be worth watching. After all, if the FDA will approve drug submissions even when the clinical trials don't prove their effectiveness, the possibilities for new "treatments" of "disorders" become limitless. I would have thought it was a no-brainer: no effectiveness, no approval. That there was even a question of which way the FDA might go says a whole lot about the cozy relations between Big Pharma and the FDA.

No comments: